Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy.
Laura N EadieElias LagonikElyse C PageCaitlin E SchutzSusan L HeatleyBarbara J McClureMichelle O ForgioneDavid T O YeungTimothy P HughesDeborah L WhitePublished in: Blood (2024)